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Introduction
The road to translational discovery and clinical innovation is 
wrought with logistical, financial, and regulatory hurdles. The 
“translational valley of death,” as it is often described, is a challenge 
further compacted by increasing financial costs and limited 
funding; scarcity of integrated information systems; asset gaps 
and redundancy; and deficient mechanisms for identifying and 
linking scattered resources.1,2 The National Institutes of Health 
(NIH) Clinical and Translational Science Award (CTSA) program 
has charged 61 of the nation’s top academic health centers with 
developing solutions and systems to address the major bottlenecks 
in translational research, with the goal of more rapid development 
of effective treatments for patients.3–6
As the NIH-designated academic institutional homes for 
clinical and translational (C&T) research, it is the responsibility 
of the CTSA Consortium to develop and implement strategies for 
working through these barriers, ensuring that its collective and 
individual investments lead to discoveries that rapidly translate 
into improved clinical care. The CTSA Consortium sites host 
valuable programs and infrastructure supporting translational 
science and are required to provide a home for these resources. 
These include NIH-funded high-end instrumentation and core 
lab equipment, clinical research centers, biobanks, innovative 
process-driven programs to facilitate research, and networked 
tools that enable cutting-edge research and education. However, 
even within each institution, resources can be difficult to quickly 
identify and access. Many sites have therefore developed local 
solutions including Web-based systems to search and request 
core services, staff that serve as resource navigators, and research 
support programs that offer various services.7 See Table 1 for 
anticipated stakeholder use cases, which are trying to be addressed 
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Abstract
The 61 CTSA Consortium sites are home to valuable programs and infrastructure supporting translational science and all are charged 
with ensuring that such investments translate quickly to improved clinical care. Catalog of Assets for Translational and Clinical Health 
Research (CATCHR) is the Consortium’s effort to collect and make available information on programs and resources to maximize ef-
ficiency and facilitate collaborations. By capturing information on a broad range of assets supporting the entire clinical and translational 
research spectrum, CATCHR aims to provide the necessary infrastructure and processes to establish and maintain an open-access, 
searchable database of consortium resources to support multisite clinical and translational research studies. Data are collected using 
rigorous, defined methods, with the resulting information made visible through an integrated, searchable Web-based tool. Additional 
easy-to-use Web tools assist resource owners in validating and updating resource information over time. In this paper, we discuss the 
design and scope of the project, data collection methods, current results, and future plans for development and sustainability. With 
increasing pressure on research programs to avoid redundancy, CATCHR aims to make available information on programs and core 
facilities to maximize efficient use of resources. Clin Trans Sci 2014; Volume 7: 100–107
Keywords: CTSA, resource identification, translational discovery
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by the Consortium. Yet, nationally, the challenges identifying 
needed resources remain. Thus, these valuable assets must be 
identified and profiled on a national scale.
These problems have been apparent; numerous surveys have 
captured national or regional resource-related data during the 
evolution of the network, but to date, there has been no concerted 
effort to consolidate and make data from those efforts organized 
and publicly available. Despite publication of Consortium survey 
results,8–10 data quickly become outdated and are often published 
in aggregate, making resources therein unidentifiable by site and 
with no contact information for resources. As recommended by 
the 2013 Committee to Review the CTSA Program at the National 
Center for Advancing Translational Sciences (NCATS), the 
Consortium is positioned to “fully develop the role of facilitator 
and accelerator of clinical and translational research…” by “…
developing, refining, widely disseminating, and implementing 
novel research and health informatics tools.”11(p. 47) Catalog of 
Assets for Translational and Clinical Health Research (CATCHR) 
is the Consortium’s integrated effort to fulfill the goal of resource 
data capture and release in order to support multisite studies and 
make assets visible.
As charged by the CTSA Consortium Steering Committee 
and supported administratively by the CTSA Consortium 
Coordinating Center (C4), collectively the Lead Administrators 
at each site have enabled efficient collection of data on assets at 
their respective sites. Lead administrators are an integral part 
of the data collection process from beginning to end, working 
closely with C4 to both collect and verify data. Resource (asset) 
identification, data collection, and routine maintenance are 
facilitated at the individual site level to ensure thoroughness and 
accuracy of site-specific data for the lifespan of this project. Lead 
administrators identify contact information for assets, facilitate 
timely submission of survey responses, and coordinate site-wide 
data refreshes over time.
CATCHR captures information on a broad range of 
assets supporting the entire C&T research spectrum, from 
early discovery to comparative effectiveness and community 
engagement research. The mission is to provide the necessary 
infrastructure and efficient processes to establish and maintain a 
searchable database of Consortium resources to support multisite 
C&T research studies. Data have been and will be collected using 
rigorous, defined methods, with the resulting information made 
available in a Web-based tool that will be searchable, linkable, and 
open-access with Consortium data all in one place. CATCHR 
also aims to make enabling assets visible to the Consortium as 
a whole; NIH, potential research collaborators and stakeholders 
including industry, other federal sponsors, disease foundations, 
community partners, and to the lay public in order to streamline 
central and generalizable translational functions such as those 
shown in Figure 1.
Methods
The design and scope of the project focus on assets at CTSAs that 
are: (1) not consistently captured elsewhere; (2) higher-dollar 
public investments; and (3) necessary for key steps of translational 
science. The first step in the cataloging process is asset selection 
and definition with the help of domain experts. Once an asset 
and variables are defined, C4 assesses the best approach to data 
collection. These methods include use of public data, survey tools, 
or mixed methods. Once preliminary data have been collected, 
these are vetted through a review/approval process with CTSA 
sites before public release. Figure 1 depicts an overview of general 
methods and approach to sustainability of the tool.
Selecting and defining assets
Selecting and accurately defining CATCHR assets has been a 
collaborative effort involving content domain experts, Consortium 
groups, and a variety of committees. The growing list of over 30 
assets is highly diverse and spans the entire spectrum of C&T 
research, from early discovery to community-engaged and 
comparative effectiveness research. The assets were chosen based 
on scope, value, research enablement, uniqueness, being definable, 
and/or by demand. An asset is defined based on expert feedback 
and a critical evaluation of existing peer-reviewed literature. 
CTSA investigators and leadership are engaged throughout the 
process to ensure that asset definitions reflect the most current 
trends and developments within the C&T landscape. The selection 
of variables is tailored to each unique asset to ensure that data 
collected are both valuable and structured. This ensures that 
the approach to identifying resources is both methodical and 
deliberate. Quality data collection resulting from a controlled set 
of unique variables is crucial for the effectiveness of CATCHR’s 
targeted search mechanisms.
Stakeholder use cases for resource identification
Academic medical 
centers
Maximize use of high-dollar  
instrumentation investment
Research foundation Rapidly launch clinical studies in rare 
 disease cohorts
Industry Sponsor small molecule and biologics 
 discovery for novel therapeutic targets
Individual 
 investigators
Identify project-specific instrumentation, 
services, and collaborators
Government Explore geographic distribution of 
 infrastructure and expertise
Table 1. Potential resource identification use cases for various stakeholder groups.
Figure 1. Overview of general CATCHR methods and sustainability approach.
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Criteria for choosing variables are dependent on both the 
asset definition and the distinct needs of associated stakeholder 
groups in relation to that specific asset. The variables collected are 
meant to represent a high-level characterization of each asset. In 
order to ensure that data remain relevant, variables collected for 
each asset focus not on highly granular data that change rapidly, 
but rather on more static information, such as general services 
provided. While selected variables are unique to each individual 
asset, they must also remain comprehensive in order to broadly 
characterize the resources available at each CTSA institution and 
its affiliate sites. In this way, industry, foundation, and academic 
collaborators alike can easily identify which institutions have the 
resources and/or expertise needed for a particular project or in an 
effort to streamline central translational functions such as clinical 
trial start-up and formation of research networks.
Data collection
A variety of data collection methods are being utilized depending 
on the complexity and public availability of the asset variables. 
When possible, public data sources are used, such as Websites 
and publications, followed by phone or e-mail interviews, 
with the goal of decreasing the work burden on the contacts 
and administrators at the CTSA sites. For more complex assets 
with well-defined owners, REDCap surveys have been used to 
collect information on resources such as Clinical Research Units, 
Local Pilot Funding Programs, and Electronic Health Records. 
Intensive methodical tracking and follow-up with the sites has 
been required throughout the process.
One approach to preliminary data collection is the use of 
publicly available, verified sources of information. This process 
includes mining reliable sources of public information and the 
assessment of contractual agreements. These public sources 
include databases and registries that are curated and regularly 
maintained; examples include; NIH listings and grant databases, 
FDA facility registries, network listings, and researcher profiles. 
For some assets, the CATCHR team worked with Consortium 
groups to make use of historical survey tools and data. In some 
instances, previously collected data were integrated into the 
CATCHR framework. The CATCHR team also worked with 
Consortium groups to support the dissemination, tracking, and 
follow-up of Consortium surveys as an extension of the CATCHR 
project.
Phone or e-mail interviews were instituted as a means of 
verifying data collected from public sources of unsubstantiated 
information such as Web pages, fact sheets, and presentations. 
Once a search for publicly accessible information has been 
exhausted, individual resource administrators are contacted 
and encouraged to review the collected data and fill in gaps 
of information where possible. As a result of this personal 
interaction, many investigators and facility directors throughout 
the Consortium are newly introduced to the mission and 
leveraging power of the CTSA Consortium as a whole. Though 
cataloged resources are interwoven within the CTSA landscape, 
many resources are not directly affiliated with each institution’s 
CTSA program. In this way, CATCHR serves as an introduction 
mechanism, essentially binding the breadth of the Consortium 
with its many indirectly related components and institutionally 
supported resources.
In some instances where public data are sparse or unavailable, 
C4 works with domain experts to develop survey questions 
relevant to asset data collection and then creates a REDCap survey 
tool. In collaboration with appropriate Consortium domain 
experts and/or committees and CTSA site institutional leaders 
(ILs), as appropriate, the CATCHR team identifies appropriate 
target participants and disseminates, tracks, and performs quality 
assurance of data collected before integration into the centralized 
framework.
To increase efficiency and leverage existing infrastructure, 
REDCap12 is used as the mechanism for collecting survey data 
and centrally storing, managing, and querying all collected data. 
Integrated with the online CATCHR user interface, REDCap 
editing tools will remain active indefinitely to support an evolving, 
dynamic database that will serve as a current reflection of 
resources available within the Consortium.
Data validation
The accuracy of the data is critical to the success of the project 
in achieving its goals. An IL, such as a PI, a Lead Administrator, 
or a person appointed by the PI or Lead Administrator assumes 
responsibility for monitoring the development of the initial data 
set and supervising regular review and management to assure the 
long-term utility, dependability, and sustainability of CATCHR. 
For this purpose, all CATCHR data will be reviewable and editable 
by individual CTSA sites at all times; see Figure 2 for a screenshot 
of the online data editing interface.
Site-level data review and edit rights are held by all CTSA Lead 
Administrators. It is expected that each site’s data maintenance 
and updates will be ongoing for the life of the initiative. Upon 
completion of preliminary data collection on each asset, C4 
notifies the CTSA Lead Administrators or ILs of data availability 
for review prior to public release, and the timeline for public data 
release and publication through the user interface. Released data 
will include a “date of last edit” to allow users discretion over 
which data are used, and data not updated within 12 months will 
be suppressed with an automated notification to the institutional 
contacts. Data will be refreshed and curated by sites, and asset 
questions will be refined as needs, technologies, and Consortium 
directions change over time; historical data will be archived. To 
maintain flexibility and resource usefulness, C4 will carry out data 
collection on new assets and update definitions and variables as 
needed and requested by stakeholders.
Results
Roughly 30 assets were initially proposed when the CTSA 
cataloging effort first commenced. These assets contain an 
average of 12 variables each, and over 1,200 data elements 
have been collected, to date. More than 700 participants have 
directly contributed data, and over 1,300 unique C&T resources 
(i.e., programs, infrastructure, instrumentation, etc.) from 61 
institutions and affiliate sites have been cataloged thus far. These 
assets were strategically chosen to represent the diversity and 
complexity of the Consortium’s translational mission and 
areas of research. These assets can be categorized according 
to utility and represent a wide array of enabling resources; 
research infrastructure and instrumentation; research processes 
and support mechanisms; networking and collaboration tools; 
as well as patient-oriented research programs. Examples of 
assets include drug discovery programs, biobanks, medicinal 
chemistry facilities, commercialization facilitation programs, 
national and regional network memberships, community 
engagement research infrastructure, and clinical research units 
(see Figures 3 and 4 for sample aggregate data); see Figure 5 
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and Table S1 for a complete listing of assets with definitions 
and variables.
An online searchable interface (see Figure 6) will allow users 
to search assets based on selected criteria in a Boolean manner. 
Users provide their name and a few details about their search, 
which will unlock access to asset contact information and allow 
the CATCHR team to track user metrics. Output data include the 
CTSA site, name of the asset or facility, contact information for 
each asset, and a date of last edit so that users may be informed 
of the “freshness” of the data.
Discussion
Anticipated use
CATCHR was constructed as a curated, Consortium-wide 
inventory of C&T assets on the principle that NIH-funded 
resources should be visible, quickly identifiable, and easily 
accessible for their intended users. By collating together data of 
this magnitude, the utility of the tool is estimated to be as diverse 
as the approximately 61 medical institutions that it represents. 
CATCHR has created an opportunity for the Consortium to 
make data available to multiple constituents, including NIH/
government, the lay public, the media, the CTSA Consortium 
sites, disease foundations, investigators and research teams, 
pharmaceutical and biotech companies, translational science 
societies, venture capital groups, CTSA site resource navigators, 
consortium committees and workgroups, and state and local health 
departments in order to achieve goals outlined in use cases shown 
above (Table 1). Projected utility among these diverse groups 
is expected to include study planning and initiation, funding 
offering development, information gathering for reporting, 
resource development planning, resource-based project planning, 
funding agency planning, and partnership formation. Uses of 
CATCHR for these applications will be tracked over time to guide 
further resource development. Establishing new partnerships and 
projects is a major emphasis of the project. Because CATCHR 
highlights not only the individual, but the cohesive strengths of 
the Consortium sites, it is expected that the resource will aid in 
existing collaborative research efforts and entice the start-up of 
new multisite projects.
Integration of feedback and support of consortium 
participation/use
To improve the quality and usability of the resource and allow for 
external guidance and review, qualitative methods for evaluating 
the tool are in place. Metrics reported by users including 
Figure 2. CATCHR data editing interface including options for editing existing data, forwarding edit rights to others, and adding new resources.
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Figure 3. Aggregate data on physical infrastructure, instrumentation, and expertise assets. (A) Represents 44 high-throughput screening facilities from 40 sites. (B) Repre-
sents 31 biobanks from 31 sites. (C) Represents 81 high-end instruments from 36 sites as awarded through the NIH HEI grant program. (D) Represents 24 drug discovery 
centers from 23 sites.
Figure 4. Aggregate data on patient-oriented infrastructure assets. (A) Represents 118 Clinical Research Units from 59 sites. (B) Represents 20 clinical trial coordinating 
centers from 19 sites. (C) Includes 41 research data warehouses from 37 sites. (D) Represents 59 vendor-based EHR systems from 46 sites.
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stakeholder group identity, geographic location, purposes 
of searches, structured and unstructured feedback, and data 
accessed will inform continuous development and improvement. 
This type of ongoing evaluation will help to: (1) ascertain key 
information needs among target users; (2) 
assess and understand expected search 
patterns by various user groups; and (3) 
explore the utility and appropriateness of 
the information as presented in various 
visual formats.
CATCHR will also grow to better reflect 
the needs of its users by evolving based 
on their utilization of the tool. User data 
collected through the interface, such as assets 
most frequently accessed and problems 
frequently reported, will be used to guide 
review prioritization. The C4 will maintain 
an immediate feedback communication 
option within CATCHR that will prompt 
users to suggest modifications or additions 
to asset display. These online feedback 
methods will ensure that CATCHR develops 
in parallel with the goals of the Consortium 
and its constituents. Of course, integrating 
feedback and promoting Consortium-
wide ownership of the tool will require 
continuous, critical evaluation that moves 
beyond even the most rigorous of qualitative 
evaluation methods.
Future plans for sustainability
Plans are in place to affirm that CATCHR 
remains curated as a sustainably updated 
resource. To ensure that data remain 
current and reflective of the existing C&T 
landscape, it will be strategically refreshed 
and curated by sites, and asset questions 
will be refined as needs, technologies, and 
Consortium directions change over time. 
In terms of maintaining current data, data 
editing tools will remain active indefinitely, 
creating an evolving, dynamic database that 
will always serve as a current reflection of 
resources available within the Consortium. 
As CATCHR serves as a centralized tool 
representing the Consortium’s resources, 
its ultimate utility involves joint efforts of 
all 61 sites. Data collection on new assets 
will continue and updating definitions and 
variables will be a part of the administrative 
functions of the coordination center. 
In conjunction with regular yearly data 
revisions, in-depth data reviews on two to 
four assets will be performed per year in order 
to capture changes in asset definitions and 
relevance as technologies and research evolve 
over time. User statistics will be maintained so 
that assets that are rarely or never viewed may 
be recommended for elimination. Public data 
will also be searched to verify data accuracy.
Linkage to other resources
CATCHR was developed to support the visibility and accessibility 
of Consortium-wide resources, not in competition with existing 
resource identification services, but rather in conjunction with 
Figure 5. Distribution of completed and planned CATCHR assets along the translational science spectrum.
106 VOLUME 7 • ISSUE 2 WWW.CTSJOURNAL.COM
Shirey-Rice et al. n The CTSA Consortium’s CATCHR
them. CATCHR fulfills an intrinsic need within the research 
community in that it provides both a broad and high-level view 
of the CTSA Consortium’s very unique and valuable scientific 
portfolio. Still, its value can be optimized by leveraging the power 
of existing resources that meet similar, but distinct needs. Linking 
to resources such as Science Exchange13 and eagle-i,14,15 would 
add transaction functionality and granularity for core-like assets, 
model organisms, and reagents.
Conclusions
With increasing cuts to NIH budgets and building pressure on 
research programs to avoid redundancy, CATCHR can help to 
make available information on equipment, core facilities, and 
programs to maximize efficient use of resources. Core facilities 
provide critical access to services, expert consultations, and 
instrumentation that is required for cutting-edge translational 
research. They represent large federal and institutional investments 
that are often underutilized and duplicated within institutions 
and across geographical regions.16 One of the major barriers to 
utilization of cores and research support programs is the lack of 
readily available, accurate information. Under the CTSA program, 
CATCHR aims to provide this consolidated source of information 
on contacts and general services. While Web-based search engines 
yield somewhat useful but varying results, their utility is limited 
by accuracy of linked Websites (often containing outdated 
information). Manual searches using multiple search engines 
and tools is also extremely time consuming for investigators and 
can be the rate-limiting step in establishing collaborations and 
initiating multisite studies. By combining data and information 
from many sources in one place and making it searchable and 
publicly available, the burden is drastically decreased.
CATCHR provides value and time savings but is not designed 
to meet all project and resource identification needs. For instance, 
there are no plans to include detailed data on model organisms, 
highly technical reagents or assays, or transactional capabilities 
to support purchase of core services. The CATCHR team does, 
however, plan to catalog and link resources listed in other 
programs that provide those valuable functions such as eagle-i and 
Science Exchange. CATCHR also does not currently contain data 
on resources at non-CTSA institutions but may have the capacity 
Figure 6. CATCHR online user interface depicting an example search for high-throughput screening and medical chemistry facilities.
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to do so in future development. Finally, the success of the project 
will be driven (and limited) by efforts by ILs, lead administrators, 
and resource contacts to keep data current. For more information, 
please visit https://www.ctsacentral.org/catchr/portfolio.
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